Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

NCT03079531 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Papulopustular Rosacea

Interventions

DRUG: Secukinumab

Sponsor

Anne Chang